Logo

Ziopharm Oncology's Controlled IL-12 Platform Receives EMA's COMP Positive Recommendation for Orphan Drug Designation to Treat Glioma

Share this

Ziopharm Oncology's Controlled IL-12 Platform Receives EMA's COMP Positive Recommendation for Orphan Drug Designation to Treat Glioma

Shots:

  • EMA’s Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion recommending Ziopharm’s Controlled IL-12 platform (Ad-RTS-hIL-12 + veledimex) for ODD candidate for the treatment of glioma
  • EMA’s ODD provides regulatory and financial incentives to the company for developing & commercializing therapies for life-threatening diseases no more than five in 10-000 persons in EU and granting an additional 10yrs. period of marketing exclusivity in the EU post approval
  • Ziopharm’s Controlled IL-12 platform is an investigational gene therapy designed to target human interleukin 12 (hIL-12) of the immune system and has received FDA’s FT designation for the treatment of rGBM in adults

Click here to­ read full press release/ article | Ref: Ziopharm | Image: Immuno-Oncology News


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions